DLL3 and small cell lung carcinoma: The safety of antibody-drug conjugate (ADC) drugs (Uprety et al., 2021) and the refractory nature of SCLC have led to less satisfactory clinical trials of drugs targeting DLL3 in SCLC (Johnson et al., 2021; Mansfield et al., 2021; Matsuo et al., 2021), there are still different drug forms being actively explored.